- Home
- MNMD vs PSBD Comparison
MNMD vs PSBD Comparison
Compare MNMD & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- PSBD
- Stock Information
- Founded
- MNMD 2019
- PSBD 2009
- Country
- MNMD United States
- PSBD United States
- Employees
- MNMD N/A
- PSBD N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- PSBD
- Sector
- MNMD Health Care
- PSBD
- Exchange
- MNMD Nasdaq
- PSBD Nasdaq
- Market Cap
- MNMD 509.2M
- PSBD 454.5M
- IPO Year
- MNMD N/A
- PSBD 2024
- Fundamental
- Price
- MNMD $9.61
- PSBD $13.93
- Analyst Decision
- MNMD Strong Buy
- PSBD Buy
- Analyst Count
- MNMD 7
- PSBD 4
- Target Price
- MNMD $24.71
- PSBD $14.38
- AVG Volume (30 Days)
- MNMD 1.3M
- PSBD 46.8K
- Earning Date
- MNMD 07-31-2025
- PSBD 08-06-2025
- Dividend Yield
- MNMD N/A
- PSBD 12.62%
- EPS Growth
- MNMD N/A
- PSBD N/A
- EPS
- MNMD N/A
- PSBD N/A
- Revenue
- MNMD N/A
- PSBD N/A
- Revenue This Year
- MNMD N/A
- PSBD N/A
- Revenue Next Year
- MNMD N/A
- PSBD N/A
- P/E Ratio
- MNMD N/A
- PSBD N/A
- Revenue Growth
- MNMD N/A
- PSBD N/A
- 52 Week Low
- MNMD $4.70
- PSBD $11.51
- 52 Week High
- MNMD $10.49
- PSBD $16.83
- Technical
- Relative Strength Index (RSI)
- MNMD 56.17
- PSBD 49.59
- Support Level
- MNMD $7.96
- PSBD $13.59
- Resistance Level
- MNMD $10.49
- PSBD $14.09
- Average True Range (ATR)
- MNMD 0.55
- PSBD 0.34
- MACD
- MNMD -0.06
- PSBD 0.01
- Stochastic Oscillator
- MNMD 65.22
- PSBD 56.71
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.